Researchers’ blood cancer breakthrough

August 10, 2011

Researchers at the University of Southampton have discovered clues to why many patients do not respond to a standard drug for the blood cancer lymphoma, raising hopes that more effective treatments can be designed.

Non-Hodgkin’s is the sixth most common cancer in the UK and causes around 4,500 deaths a year in the UK, with a rise in cases reported. The most successful advance in treatment in recent years has been a drug called rituximab, which works by ‘tagging’ the surface of the tumour so they can be sought out and destroyed by the patient’s own immune system.

Unfortunately, an estimated 30% of patients do not respond to treatment. Professors Mark Cragg, Peter Johnson and Martin Glennie and their teams at the University Of Southampton Faculty Of Medicine are investigating reasons behind this.

They found that in some lymphoma patients, after binding to the surface of the cancer cells, rituximab is quickly internalised inside the cell. This means that the drug does not work as it should and immune cells cannot seek out and kill the cancer cells as effectively.

The results of the team’s research, which was co-funded by the charity Leukaemia & Lymphoma Research, the Medical Research Council, Research UK and Tenovus, Cardiff are published online in the medical journal Blood.

Through a series of laboratory tests, the Southampton scientists crucially noticed that rituximab is internalised much faster by the lymphoma cells when a molecule called ‘FcgRIIb’ is also present at high levels. In a small, preliminary analysis, the researchers found that those patients with high amounts of this molecule on their lymphoma were less likely to be treated successfully. They are now moving forward with a much bigger analysis to confirm their findings.

Professor Cragg said: “The discovery that high levels of FcgRllb on lymphoma cells can determine how effective rituximab will be could be very significant. It may be that different, non-internalising antibodies are needed for certain patients. FcgRllb is also a potential target for new drugs to work alongside standard treatments.”

Dr. David Grant, Scientific Director at Leukaemia & Lymphoma Research, said: “Treatment for non-Hodgkin’s lymphoma has made rapid progress but clearly a significant number of patients do not respond to drugs like rituximab. Understanding exactly why they don’t respond is vital so that new drugs can be designed to make sure that every patient survives.”

Dr. Ian Lewis, Associate Director of Research at Tenovus, said “In addition to helping us devise new drugs and therapeutic strategies for the treatment of lymphoma, this discovery could also help us to identify those who will not respond to treatment with rituximab and therefore offer them alternative, more effective treatments at a much earlier stage”.

Explore further: Key cause of bone marrow failure identified

Related Stories

Key cause of bone marrow failure identified

May 3, 2011

(Medical Xpress) -- Researchers funded by Leukaemia & Lymphoma Research and the Medical Research Council (MRC) have identified one of the first steps that can cause bone marrow failure and eventually lead to blood cancers. ...

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.